A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
NCT06805825
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Gastrointestinal Stromal Tumors
- Small-cell Lung Cancer
- Adenoid Cystic Carcinoma
- Uveal Melanoma
- Neuroendocrine Tumors
- Chromophobe Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Novelty Nobility, Inc.
- Last updated on ClinicalTrials.gov
- September 23, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- University of Michigan Hospitals · Ann Arbor, MI
Ohio · 1
- Case Comprehensive Cancer Center · Cleveland, OH
Oregon · 1
- Oregon Health & Science University · Portland, OR
Texas · 1
- The University of Texas MD Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.